Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy
Grössmann N
Record ID 32016000988
English
Authors' recommendations:
The combined use of afatinib and paclitaxel for this indication has been investigated in the LUX–Lung 5 trial, a randomised, open-label phase III study. Although the study shows a significant gain in median PFS, the treatment with afatinib–paclitaxel is associated with a higher expanse of AEs and relatively high costs. In addition, more data will be required due to the unexpected low number of enrolled patients and the subsequent lower power of the study.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/1089/
Year Published:
2016
URL for published report:
http://eprints.hta.lbg.ac.at/1089/1/DSD_HSO_Nr.59.pdf
URL for additional information:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms
- Quinazolines
- Afatinib
- Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Gefitinib
- Antineoplastic Combined Chemotherapy Protocols
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.